Rebirthel
Rebirthel is a company dedicated to developing innovative immunotherapy treatments, including cancer and infectious disease therapies, utilizing advanced T-cell technology derived from iPS cells. Their mission is to provide accessible and effective immune cell therapies to improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Off-the-shelf iPS-derived cytotoxic T cell therapeutic (pipeline)
Pipeline cell therapy consisting of cryopreserved, engineered cytotoxic T cells derived from pluripotent stem cells, intended for treatment of cancer and severe viral infections.
Off-the-shelf iPS-derived cytotoxic T cell therapeutic (pipeline)
Pipeline cell therapy consisting of cryopreserved, engineered cytotoxic T cells derived from pluripotent stem cells, intended for treatment of cancer and severe viral infections.
Services
Granting research licenses and transferring cell engineering technologies to external pharmaceutical research programs under contract.
Joint development projects with medical centers and research institutes to advance preclinical and translational cell therapy programs.
End-to-end preclinical development services from antigen identification and TCR cloning through generation of engineered iPS-derived T cell products for in vivo testing.
Granting research licenses and transferring cell engineering technologies to external pharmaceutical research programs under contract.
Joint development projects with medical centers and research institutes to advance preclinical and translational cell therapy programs.
End-to-end preclinical development services from antigen identification and TCR cloning through generation of engineered iPS-derived T cell products for in vivo testing.
Expertise Areas
- iPS-derived T cell engineering
- Cell therapy manufacturing and scale-up
- Cancer immunotherapy
- Infectious disease immunotherapy (including COVID-19 applications)
Key Technologies
- Induced pluripotent stem cell (iPS) differentiation
- T-cell receptor (TCR) gene engineering
- Allogeneic/off-the-shelf cell therapy production
- Cryopreservation of cell therapy products
News & Updates
A news article about the use of regenerated Killer T cells for cancer immunotherapy.
Rebirthel signed a research license agreement with Otsuka Pharmaceutical to provide technology for cancer treatment research.
Kyoto University Professor Hiroshi Kawamoto's research on COVID-19 treatment using iPS cell-derived T cells was featured in Yomiuri Shimbun.
Rebirthel and Fukuoka University of Medical Sciences entered into a joint research contract to develop new COVID-19 treatments using universal Killer T cells.
Research on COVID-19 treatment using T cells was featured on TBS's 'Report Special' program.
Interview footage of Rebirthel Director Hiroshi Kawamoto visiting Fukuoka University of Medical Sciences.
A news article about the use of regenerated Killer T cells for cancer immunotherapy.
Rebirthel signed a research license agreement with Otsuka Pharmaceutical to provide technology for cancer treatment research.
Kyoto University Professor Hiroshi Kawamoto's research on COVID-19 treatment using iPS cell-derived T cells was featured in Yomiuri Shimbun.
Rebirthel and Fukuoka University of Medical Sciences entered into a joint research contract to develop new COVID-19 treatments using universal Killer T cells.
Research on COVID-19 treatment using T cells was featured on TBS's 'Report Special' program.
Interview footage of Rebirthel Director Hiroshi Kawamoto visiting Fukuoka University of Medical Sciences.